EHJ 2012;33(12):1635-1701

Classes of recommendations

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Levels of evidence

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Quality of evidence used in GRADE

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Percentage of the decrease in deaths from coronary heart disease attributed to treatments and risk factor changes in different populations

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Guideline recommendations vs. achievements in patients with established coronary heart disease in EUROASPIRE III

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations regarding risk estimation

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Relationship between total cholesterol/HDL cholesterol ratio and 10-year fatal CVD events in men and women aged 60 years with and without risk factors, based on a risk function derived from the SCORE project.

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Impact of combinations of risk factors on SCORE 10-year risk of fatal cardiovascular disease

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

SCORE chart: 10-year risk of fatal cardiovascular disease (CVD) in countries at high CVD risk based on the following risk factors: age, sex, smoking, systolic blood pressure, and total cholesterol.

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

SCORE chart: 10-year risk of fatal cardiovascular disease (CVD) in countries at low CVD risk based on the following risk factors: age, sex, smoking, systolic blood pressure, and total cholesterol.

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Relative risk chart for 10-year mortality.

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Illustration of the riskage concept.

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations for genetic testing

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendation regarding age and gender

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendation regarding psychosocial factors

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations for inflammatory biomarkers

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations for thrombotic biomarkers

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations regarding imaging methods

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations regarding other diseases with increased risk for cardiovascular disease

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations for behavioural change

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations regarding smoking

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Modified World Health Organization (WHO) smoking cessation algorithm.

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

The Five As for a smoking cessation strategy for routine practice

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Nutrition messages

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendation regarding nutrition

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations regarding physical activity

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendation regarding body weight

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Potential adverse cardiovascular effects of increasing body weight

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Measures of general obesity and abdominal adiposity

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations on blood pressure

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Definitions and classification of blood pressure levels

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Blood pressure thresholds for definition of hypertension with different types of blood pressure measurement

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Factors influencing prognosis in hypertension

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations on diabetes mellitus

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations on management of hyperlipidaemia

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Intervention strategies as a function of total cardiovascular risk and low-density lipoprotein cholesterol level

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Selected drugs that may increase risk of myopathy and rhabdomyolysis when used concomitantly with statin (CYP3A4 inhibitors/ substrates or other mechanisms)

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations on antithrombotic therapy

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations for promoting medication adherence

ESC GUIDELINES 2012

EHJ 2012;33(12):1635-1701

Recommendations on the management of psychosocial factors

ESC GUIDELINES 2012

EHJ June 2012

Core questions for the assessment of psychosocial risk factors in clinical practice

ESC GUIDELINES 2012

EHJ June 2012

Recommendations for behavioural change

ESC GUIDELINES 2012

EHJ June 2012

Recommendations on the management of psychosocial factors

ESC GUIDELINES 2012

EHJ June 2012

Reasons for medication non-adherence according to the World Health Organization

ESC GUIDELINES 2012

EHJ June 2012